Conference on Retroviruses and Opportunistic Infections
The annual Conference on Retroviruses and Opportunistic Infections (CROI 2017) "brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious disease."
Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.
At CROI 2017, John W. Ward, MD, CDC, explained his team has been concentrating on one particular health effect: transmission of hepatitis C from mother-to-child at the time of birth. This is showing them increases in children now becoming infected with hepatitis C, so itâ€™s a growing problem among young people and their children.